Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Partner Fund Management and Jounce Therapeutics Inc (JNCE)

Published on October 2, 2017 at 10:12 am by Insider Monkey Staff in Hedge Funds

Page 1 of 13

Jounce Therapeutics Inc (NASDAQ:JNCE): Christopher Medlock James’ Partner Fund Management filed an amended 13D.

You can check out Partner Fund Management’s latest holdings and filings here.

Please follow Partner Fund Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Partner Fund Management or update its stock holdings.

Follow Christopher Medlock James's Partner Fund Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Partner Fund Management	0	1,727,943	0			5.4%
Partner Fund Management GP	0	1,727,943	0			5.4%
Partner Investment Management	0	14,265	0			Less%
Partner Investment Management GP	0	14,265	0			Less%
Brian D. Grossman	0	1,742,208	0			5.4%
Christopher M. James	0	1,742,208	0			5.4%

Follow Christopher Medlock James's Partner Fund Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. )*

	Jounce Therapeutics, Inc.
(Name of Issuer)

	Common stock, par value $0.001 per share
(Title of Class of Securities)

			481116101
(CUSIP Number)

		September 19, 2017
Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule
13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Follow Jounce Therapeutics Inc.

Follow Jounce Therapeutics Inc.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13

NASDAQ:JNCE SEC 13G Filing Partner Fund Management Jounce Therapeutics Inc (JNCE)